• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

ADRIAMYCIN Drug Record

  • Summary
  • Interactions
  • Claims
  • ADRIAMYCIN wikidata:Q47520887

    Alternate Names:

    rxcui:42512

    Drug Info:

    (0 More Sources)

    Publications:

    McPherson et al., Selective sensitization of adriamycin-resistant P388 murine leukemia cells to antineoplastic agents following transfection with human DNA topoisomerase II alpha., Anticancer Res.
    Xia et al., 2004, [Effects of hypoxia on expression of P-glycoprotein and multidrug resistance protein in human lung adenocarcinoma A549 cell line]., Zhonghua Yi Xue Za Zhi
    Segura-Pacheco et al., 2006, Global DNA hypermethylation-associated cancer chemotherapy resistance and its reversion with the demethylating agent hydralazine., J Transl Med
    Goeptar et al., 1994, Cytotoxicity of mitomycin C and adriamycin in freshly isolated rat hepatocytes: the role of cytochrome P450., Cancer Res.
    Banerjee et al., 1992, Down-regulation of ras and myc expression associated with mdr-1 overexpression in adriamycin-resistant tumor cells., Cell. Mol. Biol.
    Ando et al., 2000, Decitabine (5-Aza-2'-deoxycytidine) decreased DNA methylation and expression of MDR-1 gene in K562/ADM cells., Leukemia
    Liu et al., 2000, Uncoupling ceramide glycosylation by transfection of glucosylceramide synthase antisense reverses adriamycin resistance., J. Biol. Chem.
    Ho et al., 2005, The relative contribution of CHK1 and CHK2 to Adriamycin-induced checkpoint., Exp. Cell Res.
    Nakayama et al., 2000, Effect of the lipoprotein lipase activator NO-1886 on adriamycin-induced nephrotic syndrome in rats., Metab. Clin. Exp.
    Meng et al., 1999, p53-independent increase in E2F-1 expression enhances the cytotoxic effects of etoposide and of adriamycin., Int. J. Oncol.
    Twentyman et al., 1990, Chemosensitisation by verapamil and cyclosporin A in mouse tumour cells expressing different levels of P-glycoprotein and CP22 (sorcin)., Br. J. Cancer
    Burchell et al., 1990, The role of xenobiotic glucuronidating enzymes in drug resistance of tumour tissues and cells., Int. Symp. Princess Takamatsu Cancer Res. Fund
    Mustonen et al., 1991, Activation of phospholipase A2 by adriamycin in vitro. Role of drug-lipid interactions., J. Biol. Chem.
    Koutsilieris et al., 1999, Chemotherapy cytotoxicity of human MCF-7 and MDA-MB 231 breast cancer cells is altered by osteoblast-derived growth factors., Mol. Med.
    Deffie et al., 1988, Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia., Cancer Res.
    Joles et al., 1995, Plasma triglyceride levels are higher in nephrotic than in analbuminemic rats despite a similar increase in hepatic triglyceride secretion., Kidney Int.
    Thomas et al., Free radical inactivation of rabbit muscle creatinine kinase: catalysis by physiological and hydrolyzed ICRF-187 (ICRF-198) iron chelates., Free Radic. Res.
    Barretti et al., 1995, Effects of dietary protein, angiotensin I converting enzyme inhibition and mesangial overload on the progression of adriamycin-induced nephropathy., Braz. J. Med. Biol. Res.
    Jazirehi et al., 2001, Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis., Clin. Cancer Res.
    Morsi et al., 2006, Evaluation of tumour necrosis factor-alpha, soluble P-selectin, gamma-glutamyl transferase, glutathione S-transferase-pi and alpha-fetoprotein in patients with hepatocellular carcinoma before and during chemotherapy., Br. J. Biomed. Sci.
  • ADRIAMYCIN   CKM

    Interaction Score: 3.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7834053


    Sources:
    NCI

  • ADRIAMYCIN   SRI

    Interaction Score: 1.63

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    1975203


    Sources:
    NCI

  • ADRIAMYCIN   UGCG

    Interaction Score: 1.63

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10702281


    Sources:
    NCI

  • ADRIAMYCIN   UGT1A5

    Interaction Score: 0.72

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    1966888


    Sources:
    NCI

  • ADRIAMYCIN   CYP7B1

    Interaction Score: 0.65

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8162589


    Sources:
    NCI

  • ADRIAMYCIN   AGT

    Interaction Score: 0.46

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7581027


    Sources:
    NCI

  • ADRIAMYCIN   E2F1

    Interaction Score: 0.41

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9863003


    Sources:
    NCI

  • ADRIAMYCIN   GGT1

    Interaction Score: 0.36

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16871999


    Sources:
    NCI

  • ADRIAMYCIN   LPL

    Interaction Score: 0.36

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10831167


    Sources:
    NCI

  • ADRIAMYCIN   XIAP

    Interaction Score: 0.33

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11751478


    Sources:
    NCI

  • ADRIAMYCIN   FASN

    Interaction Score: 0.31

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7723242


    Sources:
    NCI

  • ADRIAMYCIN   PLA2G1B

    Interaction Score: 0.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    2007582


    Sources:
    NCI

  • ADRIAMYCIN   DNMT1

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16893460


    Sources:
    NCI

  • ADRIAMYCIN   CHEK1

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15707569


    Sources:
    NCI

  • ADRIAMYCIN   TGFB1

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10203574


    Sources:
    NCI

  • ADRIAMYCIN   GSTP1

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    2897875


    Sources:
    NCI

  • ADRIAMYCIN   ABCC1

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15130309


    Sources:
    NCI

  • ADRIAMYCIN   TOP2A

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9494516


    Sources:
    NCI

  • ADRIAMYCIN   ABCB1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    1363885 11069027


    Sources:
    NCI

  • NCI: ADRIAMYCIN

    • Version: 14-September-2017

    Alternate Names:
    C1326 NCI drug code

    Drug Info:

    Publications:
    McPherson et al., Selective sensitization of adriamycin-resistant P388 murine leukemia cells to antineoplastic agents following transfection with human DNA topoisomerase II alpha., Anticancer Res.
    Segura-Pacheco et al., 2006, Global DNA hypermethylation-associated cancer chemotherapy resistance and its reversion with the demethylating agent hydralazine., J Transl Med
    Goeptar et al., 1994, Cytotoxicity of mitomycin C and adriamycin in freshly isolated rat hepatocytes: the role of cytochrome P450., Cancer Res.

  • Wikidata: wikidata:Q47520887

    • Version: 12-August-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21